340bemployed.org

Your Free Source for 340B News and Commentary

  • Home
  • About Us
  • Employers
  • Job Seekers
  • Advertise
  • 340B Health

HRSA Still Plans to Start Enforcing New 340B Regulation on April 1


 

Print Article

March 3, 2017—In accordance with the Trump administration’s regulatory freeze, the Health Resources and Services Administration yesterday pushed back the effective date of its 340B ceiling price and manufacturer civil monetary penalties regulation 15 days, from March 6 to March 21. [ms-protect-content id=”2799″]

HRSA said there’s no change in the date it plans to begin enforcing the regulation: April 1, the first day of the second calendar quarter.

HRSA posted the announcement for public inspection late yesterday morning. It will be formally published in the Federal Register March 6.

“The temporary delay in the effective date of this final rule is necessary to give department officials the opportunity for further review and consideration of new regulations” consistent with the administration’s regulatory freeze, HRSA explains in the announcement.

The regulation should help prevent the drug industry from overcharging 340B hospitals and other healthcare providers. In addition to specifying how 340B ceiling prices should be calculated, under the regulation a drug manufacturer that knowingly and intentionally overcharges a 340B hospital or other 340B provider can be fined up to $5,000 for each instance of overcharging. Manufacturers also will have to ensure that their distributors give providers the 340B ceiling price.

The regulation also:

  • Reaffirms and incorporates HRSA’s long-standing policy requiring a manufacturer to sell a drug at a penny if the manufacturer raises the drug’s price to such a high degree that it triggers an inflationary penalty and results in a 340B ceiling price calculation of $0.00
  • Requires manufacturers to offer refunds for overcharges on new drugs instead of maintaining the current rule requiring covered entities to request refunds
  • Makes the Department of Health and Human Services Office of Inspector General responsible for imposing 340B manufacturer civil monetary penalties, given OIG’s extensive experience applying CMPs in other contexts

The final rule cites data showing that 340B sales still make up only a tiny percentage (2.6 percent) of the overall U.S. drug market. [/ms-protect-content]

Follow us on X

340B Health Follow

340B Health is the leading advocate & resource for hospitals that serve their communities by participating in the 340B drug pricing program. #Protect340B

340BHealth
340bhealth 340B Health @340bhealth ·
4h

There’s a lot of misinformation out there about the #340B drug pricing program. Let’s clear things up🧵⬇️

Reply on Twitter 1976320035644899526 Retweet on Twitter 1976320035644899526 Like on Twitter 1976320035644899526 1 Twitter 1976320035644899526
340bhealth 340B Health @340bhealth ·
8 Oct

Fifteen years ago, Hanan Tadros struggled to manage multiple chronic conditions & prescriptions. Thanks to @UIHealth’s #340B-supported medication therapy management clinic, she now manages her health at no out-of-pocket cost and hasn’t needed insulin for 7 years. Hear her story:…

Reply on Twitter 1975988312138490364 Retweet on Twitter 1975988312138490364 Like on Twitter 1975988312138490364 Twitter 1975988312138490364
340bhealth 340B Health @340bhealth ·
7 Oct

What is the 340B program, and why does it matter for patients and communities? Let’s break it down. 🧵

Reply on Twitter 1975619321562055069 Retweet on Twitter 1975619321562055069 Like on Twitter 1975619321562055069 Twitter 1975619321562055069
Load More

RSS 340B Informed

  • An In-Depth Look at Total 340B Purchases
  • Ideas for 340B Changes Could Lead to Legislation
  • Help From 340B After a Rare Diagnosis and an Unaffordable Bill

Copyright © 2025 · 340B Health